Héma-Québec Awards Takeda Canada Two-Year Tender for Hereditary Angioedema treatment TAKHZYRO®

TORONTO, Ontario, April 28, 2022 – Takeda Canada Inc. is pleased to announce that Héma-Québec has awarded a two-year tender for TAKHZYRO® (lanadelumab injection) as the sole option for prophylaxis subcutaneous (SC) treatment for type I/II hereditary angioedema (HAE) patients. The two-year term which begins April 1, 2022, includes the option for Héma-Québec to extend… Read MoreEn savoir plus

HAEGARDA® is now available in the province of Québec

CSL Behring Canada For Immediate Release HAEGARDA® is now available in the province of Québec for the routine prevention of Hereditary Angioedema (HAE)                         attacks in adolescent and adult patients   OTTAWA, Canada, 5 February 2020. CSL Behring Canada announced that HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), is now available in the province of Québec. HAEGARDA is a… Read MoreEn savoir plus

Educational Day 2018

Saturday September 29, 2018 – 9AM to 5PM Will be held a conference day to inform about hereditary angioedema The activity is open to anyone interested or interested in the subject (patients, caregivers, professionals and health managers, representatives of the pharmaceutical industry, etc.) The morning will be dedicated to scientific conferences while a workshop will… Read MoreEn savoir plus